vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and PAMT CORP (PAMT). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $141.3M, roughly 1.4× PAMT CORP). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs -15.1%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs -12.0%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
AXSM vs PAMT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $141.3M |
| Net Profit | — | $-29.3M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | -27.0% |
| Net Margin | — | -20.7% |
| Revenue YoY | 57.4% | -15.1% |
| Net Profit YoY | — | 7.4% |
| EPS (diluted) | — | $-1.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $141.3M | ||
| Q3 25 | $171.0M | $150.3M | ||
| Q2 25 | $150.0M | $151.1M | ||
| Q1 25 | $121.5M | $155.3M | ||
| Q4 24 | $118.8M | $166.5M | ||
| Q3 24 | $104.8M | $182.6M | ||
| Q2 24 | $87.2M | $182.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $-29.3M | ||
| Q3 25 | $-47.2M | $-5.6M | ||
| Q2 25 | $-48.0M | $-9.6M | ||
| Q1 25 | $-59.4M | $-8.1M | ||
| Q4 24 | $-74.9M | $-31.6M | ||
| Q3 24 | $-64.6M | $2.4M | ||
| Q2 24 | $-79.3M | $-2.9M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | -27.0% | ||
| Q3 25 | -27.0% | -3.8% | ||
| Q2 25 | -24.5% | -7.3% | ||
| Q1 25 | -46.9% | -5.9% | ||
| Q4 24 | -61.1% | -22.6% | ||
| Q3 24 | -59.8% | 1.3% | ||
| Q2 24 | -89.5% | -0.4% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | -20.7% | ||
| Q3 25 | -27.6% | -3.7% | ||
| Q2 25 | -32.0% | -6.4% | ||
| Q1 25 | -48.9% | -5.2% | ||
| Q4 24 | -63.1% | -19.0% | ||
| Q3 24 | -61.7% | 1.3% | ||
| Q2 24 | -91.0% | -1.6% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $-1.38 | ||
| Q3 25 | $-0.94 | $-0.27 | ||
| Q2 25 | $-0.97 | $-0.46 | ||
| Q1 25 | $-1.22 | $-0.37 | ||
| Q4 24 | $-1.54 | $-1.44 | ||
| Q3 24 | $-1.34 | $0.11 | ||
| Q2 24 | $-1.67 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $83.7M |
| Total DebtLower is stronger | $70.0M | $333.9M |
| Stockholders' EquityBook value | — | $210.5M |
| Total Assets | $713.6M | $697.9M |
| Debt / EquityLower = less leverage | — | 1.59× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $83.7M | ||
| Q3 25 | $325.3M | $115.6M | ||
| Q2 25 | $303.0M | $117.3M | ||
| Q1 25 | $300.9M | $102.7M | ||
| Q4 24 | $315.4M | $110.7M | ||
| Q3 24 | $327.3M | $92.3M | ||
| Q2 24 | $315.7M | $114.0M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $333.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $325.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $210.5M | ||
| Q3 25 | $73.7M | $239.5M | ||
| Q2 25 | $73.1M | $244.9M | ||
| Q1 25 | $53.2M | $269.6M | ||
| Q4 24 | $57.0M | $277.5M | ||
| Q3 24 | $92.9M | $308.9M | ||
| Q2 24 | $102.9M | $306.7M |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $697.9M | ||
| Q3 25 | $669.3M | $715.2M | ||
| Q2 25 | $639.8M | $707.9M | ||
| Q1 25 | $596.7M | $712.6M | ||
| Q4 24 | $568.5M | $741.7M | ||
| Q3 24 | $561.5M | $756.7M | ||
| Q2 24 | $548.2M | $733.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.59× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-5.8M |
| Free Cash FlowOCF − Capex | — | $-25.0M |
| FCF MarginFCF / Revenue | — | -17.7% |
| Capex IntensityCapex / Revenue | — | 13.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-23.4M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-5.8M | ||
| Q3 25 | $1.0M | $5.9M | ||
| Q2 25 | $-32.4M | $12.2M | ||
| Q1 25 | $-43.4M | $5.0M | ||
| Q4 24 | $-26.2M | $15.2M | ||
| Q3 24 | $-18.6M | $15.5M | ||
| Q2 24 | $-30.1M | $18.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-25.0M | ||
| Q3 25 | $988.0K | $2.5M | ||
| Q2 25 | $-32.4M | $5.9M | ||
| Q1 25 | $-43.7M | $-6.8M | ||
| Q4 24 | $-26.2M | $-39.9M | ||
| Q3 24 | $-18.7M | $-33.6M | ||
| Q2 24 | $-30.2M | $4.1M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | -17.7% | ||
| Q3 25 | 0.6% | 1.7% | ||
| Q2 25 | -21.6% | 3.9% | ||
| Q1 25 | -36.0% | -4.4% | ||
| Q4 24 | -22.1% | -24.0% | ||
| Q3 24 | -17.9% | -18.4% | ||
| Q2 24 | -34.6% | 2.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 13.6% | ||
| Q3 25 | 0.0% | 2.3% | ||
| Q2 25 | 0.0% | 4.2% | ||
| Q1 25 | 0.3% | 7.6% | ||
| Q4 24 | 0.0% | 33.1% | ||
| Q3 24 | 0.1% | 26.9% | ||
| Q2 24 | 0.1% | 8.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 6.44× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
PAMT
| Freight Transportation Service | $123.1M | 87% |
| Fuel Surcharge | $18.2M | 13% |
